Browse

A novel sphingosylphosphorylcholine and sphingosine-1-phosphate receptor 1 antagonist, KRO-105714, for alleviating atopic dermatitis

DC Field Value Language
dc.contributor.authorYoon, Sae-Bom-
dc.contributor.authorLee, Chang Hoon-
dc.contributor.authorKim, Hyun Young-
dc.contributor.authorJeong, Daeyoung-
dc.contributor.authorJeon, Moon Kook-
dc.contributor.authorCho, Sun-A-
dc.contributor.authorKim, Kwangmi-
dc.contributor.authorLee, Taeho-
dc.contributor.authorYang, Jung Y-
dc.contributor.authorGong, Young-Dae-
dc.contributor.authorCho, Heeyeong-
dc.date.accessioned2020-07-15T06:00:16Z-
dc.date.available2020-07-15T15:53:56Z-
dc.date.issued2020-05-29-
dc.identifier.citationJournal of Inflammation. 2020 May 29;17(1):20ko_KR
dc.identifier.issn1476-9255-
dc.identifier.urihttps://hdl.handle.net/10371/168593-
dc.description.abstractBackground
Atopic dermatitis (eczema) is a type of inflammation of the skin, which presents with itchy, red, swollen, and cracked skin. The high global incidence of atopic dermatitis makes it one of the major skin diseases threatening public health. Sphingosylphosphorylcholine (SPC) and sphingosine-1-phosphate (S1P) act as pro-inflammatory mediators, as an angiogenesis factor and a mitogen in skin fibroblasts, respectively, both of which are important biological responses to atopic dermatitis. The SPC level is known to be elevated in atopic dermatitis, resulting from abnormal expression of sphingomyelin (SM) deacylase, accompanied by a deficiency in ceramide. Also, S1P and its receptor, sphingosine-1-phosphate receptor 1 (S1P1) are important targets in treating atopic dermatitis.

Results
In this study, we found a novel antagonist of SPC and S1P1, KRO-105714, by screening 10,000 compounds. To screen the compounds, we used an SPC-induced cell proliferation assay based on a high-throughput screening (HTS) system and a human S1P1 protein-based [35S]-GTPγS binding assay. In addition, we confirmed the inhibitory effects of KRO-105714 on atopic dermatitis through related cell-based assays, including a tube formation assay, a cell migration assay, and an ELISA assay on inflammatory cytokines. Finally, we confirmed that KRO-105714 alleviates atopic dermatitis symptoms in a series of mouse models.

Conclusions
Taken together, our data suggest that SPC and S1P1 antagonist KRO-105714 has the potential to alleviate atopic dermatitis.
ko_KR
dc.description.sponsorshipThis work was supported by a grant from the Korea Research Council for Industrial Science and Technology (KK-1933-20) to HC, under the industrial infrastructure program for fundamental technologies and Korea Institute for Advancement of Technology through the Inter-ER Cooperation Projects (R0002017) which are funded by the Ministry of Trade, Industry & Energy, Korea to YDG.ko_KR
dc.language.isoenko_KR
dc.publisherBMCko_KR
dc.subjectSphingosylphosphorylcholine-
dc.subjectSphingosine-1-phosphate receptor 1-
dc.subjectAntagonist-
dc.subjectAnti-inflammatory-
dc.subjectAtopic dermatitis-
dc.subjectHigh-throughput screening-
dc.titleA novel sphingosylphosphorylcholine and sphingosine-1-phosphate receptor 1 antagonist, KRO-105714, for alleviating atopic dermatitisko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor윤새범-
dc.contributor.AlternativeAuthor이창훈-
dc.contributor.AlternativeAuthor김현영-
dc.contributor.AlternativeAuthor정대영-
dc.contributor.AlternativeAuthor전문국-
dc.contributor.AlternativeAuthor조선아-
dc.contributor.AlternativeAuthor김광미-
dc.contributor.AlternativeAuthor이태호-
dc.identifier.doi10.1186/s12950-020-00244-6-
dc.citation.journaltitleJournal of Inflammationko_KR
dc.language.rfc3066en-
dc.rights.holderThe Author(s)-
dc.date.updated2020-06-16T09:35:21Z-
dc.citation.number1ko_KR
dc.citation.startpage20ko_KR
dc.citation.volume17ko_KR
Appears in Collections:
Seoul National University(서울대학교)Seoul National University Bulletin(서울대학교 요람) Seoul National University Bulletin, 1965-1966 (서울대학교 요람)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse